HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WEN Attorneys Meet With Top FDA Officials In ‘Continued Cooperation’

This article was originally published in The Rose Sheet

Executive Summary

CFSAN Director Susan Mayne and other high-level FDA officials met with Guthy-Renker and WEN leadership and outside attorneys in September. The substance of the meeting is being kept under wraps, but it shows FDA’s continued involvement in the WEN issue, which drove discussion at the recent Senate HELP Committee hearing on cosmetics.

You may also be interested in...



FDA Cosmetics Director: ‘Sporadic’ WEN AERs Make Case For Mandatory Reporting

In a Q&A posting, FDA Office of Cosmetics and Colors Director Linda Katz offered perspective on how the division handles adverse event reports and makes a case for mandatory AE reporting. She also explains how FDA reacted when WEN-related AERs began rolling in.

WEN Will Guthy-Renker, Chaz Dean Put Hair-Loss Ordeal Behind Them?

WEN is “new” spelled backwards, but the safety scrutiny facing the hair-care brand is anything but. FDA continues to investigate related adverse-event reports, but 2017 could be the year that Guthy-Renker and Chaz Dean dispense with the lion’s share of consumer complaints and associated payouts.

Consumers, Health Practitioners Heeded FDA’s Call For WEN-Related AEs

FDA’s safety alert in July, asking WEN users and their doctors to share information regarding hair loss-related adverse events, yielded approximately 1,000 reports in just over two months, contributing to a massive increase in cosmetic AE reports for FY 2016.

Related Content

Topics

UsernamePublicRestriction

Register

RS108638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel